HEL •
Healthcare •
Biotechnology •
Quote as of 07/29/2026 14:33
Company Profile
IndustryBiotechnology
SectorHealthcare
ExchangeHEL
Market Capitalization44.79 mln
Float14.25 mln
Earnings Date08/20/2026
Piotroski F-Score
1
/ 9
Very weak
Relative Strength
12
/ 100
Significantly lagging
Debt / Equity
-0.01
Negative equity
Dividend Yield
0.00%
No dividend
DPS
0.00
No dividend
Payout Ratio
0%
No payout
Business Description
Herantis Pharma is a Finnish drug development company focused on finding new treatments for Parkinson's disease and similar conditions. Its most advanced program centers on HER-096, a lab-designed molecule inspired by a naturally occurring brain protein, which is currently being tested in human clinical trials. The company was founded in 2008 and operates out of Espoo, Finland.
